Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Fennec Pharmaceuticals (FENC) and Cigna (CI)

Tipranks - Tipranks - Tue Apr 21, 6:18AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 10x Genomics (TXG), Fennec Pharmaceuticals (FENC) and Cigna (CI) with bullish sentiments.

Claim 30% Off TipRanks

10x Genomics (TXG)

In a report released today, Matt Larew from William Blair maintained a Buy rating on 10x Genomics. The company’s shares closed last Friday at $26.08.

According to TipRanks.com, Larew is a 1-star analyst with an average return of -2.0% and a 44.2% success rate. Larew covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Ginkgo Bioworks Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 10x Genomics with a $22.00 average price target, which is a -15.6% downside from current levels. In a report issued on April 14, TipRanks – PerPlexity also upgraded the stock to Buy with a $26.00 price target.

See the top stocks recommended by analysts >>

Fennec Pharmaceuticals (FENC)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Fennec Pharmaceuticals, with a price target of $18.00. The company’s shares closed last Friday at $6.79.

According to TipRanks.com, Amsellem is a 5-star analyst with an average return of 8.7% and a 54.0% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Collegium Pharmaceutical, and Definium Therapeutics. ;'>

Fennec Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $15.00, which is a 132.2% upside from current levels. In a report issued on April 7, Craig-Hallum also maintained a Buy rating on the stock.

Cigna (CI)

In a report released today, Jason Cassorla from Guggenheim maintained a Buy rating on Cigna, with a price target of $334.00. The company’s shares closed last Friday at $278.64, close to its 52-week low of $262.03.

According to TipRanks.com, Cassorla is a 1-star analyst with an average return of -2.5% and a 46.7% success rate. Cassorla covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Molina Healthcare, and Acadia Healthcare. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cigna with a $343.00 average price target, representing a 24.5% upside. In a report issued on April 6, Bank of America Securities also maintained a Buy rating on the stock with a $378.00 price target.

Read More on TXG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).